Benzinga | Nov 12, 2020 10:09AM EST

Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $122

Canaccord Genuity maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and lowers the price target from $145 to $122.